Listed pharmaceutical companies shrink 1Q retained earnings
64 companies whose closing accounts are in NovemberㆍDecember reduced KRW 9.8333 trillion, down by KRW 29 billion compared to the end of last year Yuhan is close to KRW 1.8 trillion… followed by GC Pharma with KRW 863.6 billion 10 companies with a loss → 7 companies… DongsungㆍKukjeㆍMyungmoon turned to black
[Newsmp] Despite listed pharmaceutical companies posting double-digit sales growth in the first quarter, the combined retained earnings decreased slightly.
Newsmp compiled the retained earnings of the listed pharmaceutical companies whose closing accounts are in NovemberㆍDecember and found that retained earnings totaled KRW 9.83333 trillion, down KRW 29 billion compared to the end of last year.
Of the 64 companies, 33 companies saw their retained earnings increase or losses decrease, while 31 companies saw their retained earnings decrease or losses increase.
In particular, Yuhan Corporation, the only listed pharmaceutical company with more than KRW1 trillion in retained earnings, increased by KRW 61.9 billion over the first quarter.
Myungmoon Pharmaceutical, which reported a loss of close to KRW 40 billion at the end of the last year, turned into a surplus, while Daewoong Pharmaceutical and Dongkook Pharmaceutical expanded their retained earnings by more than KRW 10 billion.
On the other hand, Ildong Pharmaceutical’s deficit increased from KRW 82.2 billion to KRW 121 billion, and GC Pharma and Hanmi Pharmaceutical saw their retained earnings shrink by more than KRW 10 billion.
In the meantime, as Dongsung Pharmaceutical, Kukje Pharma, and Myungmoon Pharmaceutical turned into the black, the number of companies that reported a loss decreased from 10 to 7.
As of the end of the first quarter, Yuhan Corporation had the largest retained earnings of KRW 1.792 trillion, followed by GC Pharma with KRW 863.6 billion, and Daewoong Pharmaceutical with KRW 511.9 billion.
DongKook Pharmaceutical surpassed KRW 400 billion with KRW 420.5 billion, Kwang Dong Pharmaceutical with KRW 419.8 billion, and Ilsung Pharmaceutical with KRW 402.2 billion, followed by Boryung Pharmaceutical and Chong Kun Dang Pharmaceutical with KRW 329.6 billion and KRW 302.9 billion.
In addition, Korea United Pharmaceutical, Whanin Pharmaceutical, Handok, Dongwha Pharm, Bukwang Pharmaceutical, Kyung Dong Pharmaceutical, Samjin Pharmaceutical, Daewon Pharmaceutical, and Daihan Pharmaceutical posted the KRW 200 billion mark.
Moreover, Reyon Pharmaceutical, Huons, Dong-A ST, HK inno.N, Hanmi Pharmaceutical, Sam-A Pharmaceutical, Hana Pharm, Ahn-Gook Pharmaceutical, CKD Bio, ST Pharm, Shinpoong Pharmaceutical, and Sinil Pharmaceutical exceeded KRW 100 billion, and 29 out of 64 companies have more than KRW 100 billion in retained earnings.